Auerbach, Pernille

A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine

Pharmacology and Obesity TreatmentObesity, Physical Activity, Diet

Cited by 723

Endotrophin triggers adipose tissue fibrosis and metabolic dysfunction

Sun, K., Park, J., Gupta, O. T., Holland, W. L., Auerbach, P., Zhang, N., Goncalves Marangoni, R., Nicoloro, S. M., Czech, M. P., Varga, J., et al. (2014) · Nature Communications

Adipokines, Inflammation, and Metabolic DiseasesAdipose Tissue and Metabolism

Cited by 364

Gaps to bridge: Misalignment between perception, reality and actions in obesity

Caterson, I. D., Alfadda, A. A., Auerbach, P., Coutinho, W., Cuevas, A., Dicker, D., Hughes, C., Iwabu, M., Kang, J., Nawar, R., et al. (2019) · Diabetes, Obesity and Metabolism

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 210

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial

Wadden, T. A., Tronieri, J. S., Sugimoto, D., Lund, M. T., Auerbach, P., Jensen, C., & Rubino, D. (2020) · Obesity

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 200

Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial

Frías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 188